Devanshi Kalra

Afrihealth Optonet Association — Nigeria

Medicine · Health Sciences

8h-index180citations33works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(9), Biosimilars and Bioanalytical Methods(6), Head and Neck Cancer Studies(4), Economic and Financial Impacts of Cancer(4), Palliative Care and End-of-Life Issues(3)

Publications33 total

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Blood·2025Open Access
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Blood·2025Open Access
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Blood·2025
POSTER: CT-1080 Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IECHS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
CT-1080: Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
Implementation of a CAR-T cell therapy program in India
Expert Review of Anticancer Therapy·2025· 4 cited
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
The Lancet Haematology·2025· 8 cited
Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial
Blood·2024· 2 citedOpen Access
Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
Blood·2024· 5 cited
An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024
CT-643 An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
A randomized trial to assess the effect of oral cryotherapy in the prevention of mucositis in patients with head and neck cancer receiving chemo-radiotherapy.
Journal of Clinical Oncology·2024
Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study
Medical Oncology·2023· 2 cited
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Blood·2023· 2 citedOpen Access
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Blood·2023· 12 cited
Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: A phase I/II randomized study
Research Square (Research Square)·2023Open Access
Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
Blood·2022· 5 cited
Adaptation of the Patient Reported Outcome Measurement Information System (PROMIS) tool for childhood cancer in India: A qualitative study
Psycho-Oncology·2022· 1 cited
Second-line therapy in testicular germ cell tumours: results from a tertiary cancer care centre in India
ecancermedicalscience·2022· 1 citedOpen Access
Phase 3 randomised study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer.
Journal of Clinical Oncology·2022· 6 cited
page 1 of 2Next →

Frequent Co-authors

Atharva Karulkar(14), Smrithi Ravikumar(14), Rahul Purwar(14), Lingaraj Nayak(12), Bhausaheb Bagal(12), Shreshtha Shah(11), Afrin Firfiray(11), Nandini Menon(10), Vanita Noronha(10), Kumar Prabhash(10), Juber Pendhari(9), Alok Shetty(9), Manju Sengar(9), Hasmukh Jain(8), Nirali N. Shah(7), Vijay Patil(6), Sattva S. Neelapu(6), Amit Joshi(5), Gaurav Narula(5), Archi Agrawal(5)